Plain-English translation of NCT06762964 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a 3-month study testing whether dapagliflozin—a medication originally developed for diabetes—can help adults with single-ventricle heart disease who had a Fontan procedure. The study will look at whether this medication reduces the buildup of fluid pressure in the veins and improves how well your heart works, both at rest and during exercise.
Adults who have had a Fontan procedure often struggle with fluid buildup, shortness of breath, and declining heart function over time. Researchers want to see if this medication, which has shown promise in other types of heart failure, could help reduce these complications and improve quality of life.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either the medication or a placebo (inactive pill) once daily for 3 months. During this time, you'll visit the research center multiple times for heart function tests, blood work, and measurements of fluid pressure in your veins—both while resting and during light exercise. The research team will monitor how you feel and track any changes in your symptoms and heart function.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Mayo Clinic
Enrollment target
~27 participants
Started
May 2025
Primary completion
February 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Amanda Wozniak
Mayo Clinic
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.